BridgeBio Announces Results From Phase 3 ATTRibute-CM Study Of Acoramidis Showing 81% On-Treatment Survival Rate vs 74% On Placebo
Portfolio Pulse from Benzinga Newsdesk
BridgeBio Pharma has announced results from its Phase 3 ATTRibute-CM study of Acoramidis, showing an 81% on-treatment survival rate compared to 74% on placebo. The study also showed a highly statistically significant improvement in the primary endpoint, a 50% relative risk reduction on frequency of cardiovascular-related hospitalization, and no safety signals of potential clinical concern were identified.
July 17, 2023 | 11:05 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The positive results from BridgeBio's Phase 3 study of Acoramidis could potentially boost the company's stock in the short term.
The announcement of positive results from a Phase 3 study typically has a positive impact on a biopharmaceutical company's stock. The significant improvement in the primary endpoint and the high survival rate compared to placebo are particularly promising results that could attract investor interest.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100